Overview of Aeron

Quick Facts

Property	Description
Active ingredient	Montelukast (as Montelukast sodium)
Form	Tablet (film-coated, chewable), Oral granules
Pharmacological class	Leukotriene Receptor Antagonist (LTRA)
Origin	Synthetic compound
Route of administration	Oral route (per os)

What Type of Medicine is Aeron (Montelukast)?

Aeron is a pharmaceutical preparation that belongs to the therapeutic class known as a Leukotriene Receptor Antagonist (LTRA). The active substance in Aeron is the synthetic compound Montelukast (formally Montelukast sodium). This mechanism of action is clinically recognized for its role in maintaining stable respiratory function, which sets it apart from traditional inhaled bronchodilators. Aeron is specifically designed for the consistent, long-term control of inflammation in the airways, serving as a foundational agent in preventative management rather than an immediate relief measure.

Composition, Forms, and Administration Route

The core component of Aeron is Montelukast, making it a single-ingredient product designed for targeted pharmacological action. This medication is exclusively formulated for the oral route of administration and is available in several distinct dosage forms: a film-coated tablet, a chewable tablet, and oral granules. The availability of chewable tablets and oral granules is a key feature, making the medication suitable for pediatric patients and those who may have difficulty swallowing standard tablets, which broadens its utility.

The General Purpose of Aeron

The general purpose of Aeron is to consistently maintain stability in the respiratory system by reducing the effects of specific inflammatory mediators. The drug's therapeutic benefit stems from its selective ability to block the activity of potent inflammatory chemicals called cysteinyl leukotrienes. By interrupting this specific signaling chain, Aeron helps to mitigate the underlying inflammation and maintain open airways, which is essential for preserving stable breathing function and diminishing the frequency of episodes related to chronic respiratory inflammation.

Regulatory References

Physiology, Leukotrienes - NIH

What side effects are possible with Aeron?

Official Safety Profile and Adverse Reactions

The safety profile of Aeron (Montelukast) is defined by officially documented adverse reactions classified by frequency and grouped by the affected System-Organ Class (SOC) in regulatory documents. This information focuses strictly on the potential risks identified by governmental health authorities.

Frequency-Classified Effects

Adverse reactions are categorized based on their reported frequency in regulatory data:

Common (may affect up to 1 in 10 people): Reactions include headache, abdominal pain, diarrhea, nausea, vomiting, and increases in specific liver enzyme levels (transaminases).
Uncommon (may affect up to 1 in 100 people): Documented effects include dizziness, drowsiness, dry mouth, insomnia, restlessness, irritability, and joint or muscle pain (arthralgia, myalgia).
Rare and Very Rare effects include increased bleeding tendency, tremor, and severe events such as seizures, hallucinations, and severe skin reactions.

System-Organ Classes and Serious Reactions

The most commonly affected SOC groups include Gastrointestinal Disorders and Nervous System Disorders. Official labels also highlight reactions categorized under Psychiatric Disorders, which include agitation, aggression, and the documented risk of suicidal ideation and behavior. Severe, clinically significant events explicitly listed in regulatory safety information also include forms of Hepatitis (liver injury), Angioedema (swelling beneath the skin), and rare severe skin conditions like Stevens-Johnson syndrome.

Safety Restrictions and Contextual Notes

Aeron is a maintenance medication and is officially restricted from use as a treatment for acute asthma attacks. Regulatory documents state that safety data is lacking for patients with severe hepatic impairment. Furthermore, the official safety profile includes a warning for the emergence of systemic eosinophilia and vasculitis, which has been observed in some asthmatic patients when their dose of oral corticosteroids is reduced while taking this medicine. Patients should be monitored for the occurrence of neuropsychiatric events.

Overdose and Emergency Response

Aeron Overdose and When to Seek Help

Overdose information documented by regulatory authorities indicates that symptoms of overexposure to Aeron (Montelukast) are typically consistent with the drug's established safety profile. Clinical manifestations commonly reported in overdose cases include abdominal pain, vomiting, and headache, which affect the gastrointestinal and central nervous systems. Other documented signs include somnolence (drowsiness), thirst, and psychomotor hyperactivity, the last of which is often more pronounced in pediatric cases of overexposure.

Official regulatory summaries confirm that, to date, no specific antidote or specific treatment information for Montelukast overdose is available. Consequently, the required clinical management involves symptomatic and supportive care.

Regulatory agencies mandate that emergency medical attention must be sought immediately upon any suspicion of overexposure, and the Poison Help line should be contacted for guidance. Furthermore, due to the recognized risk of serious neuropsychiatric events, patients and caregivers are officially instructed to stop using the medicine immediately and contact a healthcare professional urgently if new or worsening behavioral or mood-related changes are observed during treatment. This urgent action is required regardless of whether the event is suspected to be related to acute overexposure or general use.

Therapeutic Uses of Aeron

What Aeron treats: Main Uses and Benefits

Aeron is commonly used to help with the long-term management of asthma, addressing symptoms related to chronic inflammatory or irritative states in the airways, such as wheezing, persistent coughing, and chest tightness. It is also applied in addressing symptoms associated with allergic rhinitis, which can be seasonal or perennial, and for the prophylaxis of exercise-induced breathing difficulties. Within these applications, the medicine is primarily indicated for the prophylaxis and chronic treatment of asthma.

It provides support that helps ease the overall symptom load of these conditions. It assists with managing symptom clusters like nasal congestion, a runny nose, and sneezing, and may help patients cope more steadily with symptom fluctuations. It is relevant in contexts involving heightened systemic burden.

“This therapy is commonly used to help with conditions presenting with systemic or localized discomfort.”

Quick Fact: Relief for Respiratory and Allergic Symptoms

Domain	Target Symptom Category	Patient Benefit
Asthma	Chronic airway inflammation	Assists with maintaining functional stability.
Allergies	Nasal congestion and discharge	Contributes to easing the overall symptom load.
Exercise	Acute breathing changes	Provides supportive relief when symptoms interfere with routine activities.

Regulatory References

National Institutes of Health (NIH) DailyMed information

Eligibility and Restrictions for Use

Population Eligibility and Restrictions

Aeron is contraindicated in individuals with known hypersensitivity to Montelukast or any component of the formulation. It is not indicated for use in reversing bronchospasm during an acute asthma attack; appropriate rescue medication must be available for this purpose.

Age and Condition Rules

Regulatory documents establish minimum age thresholds for use. The medicine is approved for asthma in patients 12 months of age and older, and for perennial allergic rhinitis in patients 6 months of age and older. Use in populations younger than these official floors is not established. No overall dosage adjustment is required for older adults (65 years and over).

Conditional Use and Organ Status

Use of Aeron for allergic rhinitis is officially reserved for patients who have an inadequate response or intolerance to alternative treatments. For patients with renal impairment or mild-to-moderate hepatic impairment, no dosage adjustment is necessary. During pregnancy or lactation, use is permitted only if it is considered clearly essential.

What should I know about interactions with other medicines?

Aeron's official interaction profile is defined by its involvement in hepatic enzyme metabolism and specific restrictions documented in regulatory labeling. The medicine is extensively metabolized by the cytochrome P450 enzymes, primarily CYP2C8, and to a lesser extent, CYP2C9 and CYP3A4. This metabolic pathway is the basis for clinically significant pharmacokinetic interactions with co-administered medicines that alter enzyme activity.

Interaction Type	Interacting Substance	Official Regulatory Outcome
Increased Exposure	Gemfibrozil (CYP Inhibitor)	Increases Montelukast systemic exposure (AUC) by approximately 4.4-fold.
Reduced Exposure	Rifampicin, Phenobarbital (CYP Inducers)	Decreases Montelukast systemic exposure by up to 40%.

The profile also dictates mandatory administration restrictions. Aeron must not be abruptly substituted for oral or inhaled corticosteroids. Patients with known aspirin-sensitive asthma are required to continue the avoidance of aspirin and non-steroidal anti-inflammatory agents (NSAIDs). The co-administration of the oral granule formulation with a high-fat meal reduces the maximum plasma concentration (Cmax) by 35% and prolongs the time to peak concentration. Clinical studies indicate Montelukast does not cause clinically important changes to the pharmacokinetics of co-administered medicines such as Theophylline, Warfarin, or oral contraceptives. The chewable tablet formulation contains phenylalanine, which is a label consideration for patients with Phenylketonuria.

Mechanism of Action

Aeron's active substance, Montelukast, acts as a highly selective antagonist at the Cysteinyl Leukotriene Receptor Type 1 (CysLT1), the primary binding site for the inflammatory lipid mediator LTD4. The drug binds to this receptor, thereby blocking the binding of endogenous cysteinyl leukotrienes without activating the receptor itself. This fundamental molecular blockade initiates a mechanistic cascade that limits constrictive and inflammatory signaling originating from the CysLT pathway.

At the cellular level, this action modulates overactive physiological responses by reducing the signals for smooth muscle contraction and lessening vascular permeability (preventing fluid accumulation in the tissue). It also suppresses the infiltration of pro-inflammatory cells such as eosinophils. The final consequence is a reduction in the drivers of smooth muscle contraction and tissue swelling. This mechanism is intrinsically linked to sustained antagonism over time and is not designed for immediate physiological antagonism. Its mechanistic relevance is focused on long-term pathway interference rather than rapid physiological reversal.

Dosage and Administration Information

Aeron (Montelukast) is administered exclusively via the oral route across its available formulations, which include film-coated tablets, chewable tablets, and oral granules. The medicine is intended for once-daily administration as part of a long-term management protocol and should be continued even during periods of symptom control.

Standard Dosing and Timing

The standard daily regimen for adults and adolescents 15 years and older is a 10 mg dose. For the chronic treatment of asthma, this dose is typically taken in the evening. Pediatric dosing is specific to age: 5 mg once daily for children aged 6 –14 years, and 4 mg once daily for children aged 6 months to 5 years.

For the prophylaxis of exercise-induced bronchoconstriction (EIB), a single 10 mg dose must be taken at least 2 hours prior to exercise, provided the patient is not already taking a daily dose for another condition. If a scheduled daily dose is missed, the instruction is to take the next dose at the usual time, without taking an extra dose to compensate.

Administration Conditions and Preparation

The 4 mg oral granules are designed to be administered directly in the mouth or mixed with a spoonful of approved soft foods (such as applesauce) or 5 mL of breast milk or formula. Any prepared granule mixture must be consumed within 15 minutes of opening the packet. While film-coated tablets can be taken with or without food, it is specified that chewable tablets should be administered either 1 hour before or 2 hours after food. Dosage adjustments are generally not required for older adults or in patients with mild to moderate kidney or liver impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aeron

Evidence for Use in Chronic Asthma Management

The evidence base for Aeron's use in chronic asthma management includes Randomized Controlled Trials (RCTs) and systematic reviews that consolidate trial data. These studies were used in research exploring how symptoms change over time, focusing on functional measures like changes in FEV1 (a measure of air exhalation) and the frequency of documented exacerbations. Most pivotal trials observed responses over defined time intervals lasting 8 to 12 weeks, with findings describing patterns where outcomes were measured against a placebo group. Research also examined Aeron as an add-on to inhaled corticosteroids (ICS). In trials where Aeron was evaluated directly against ICS alone, researchers observed patterns where ICS was associated with different or larger measured changes in functional measurements. Interindividual variability in response was observed among study participants.

Evidence for Use in Allergic Rhinitis Symptoms

Aeron was studied for seasonal and perennial allergic rhinitis, with the research base consisting mainly of short-term RCTs, typically conducted over two to six weeks. Researchers monitored changes in a composite score that measures four key nasal symptoms: congestion, runny nose, sneezing, and itching. Findings describe patterns observed in the studies where use was associated with measured changes in total nasal symptom scores compared to a non-treatment group. Regulatory reviews indicate that, given the overall evidence, the product's label carries a statement stating that its use for allergic rhinitis is generally reserved for patients with an inadequate response or inability to tolerate alternative therapies.

Research Gaps and Areas of Uncertainty

The evidence highlights what is known—and what is still uncertain. Studies exploring prevention of exercise-induced breathing difficulties (EIB) are based on acute, single-dose challenge RCTs, and no evidence exists in the research to support its use for managing an acute episode once symptoms have begun. Furthermore, certain adverse events (specifically neuropsychiatric changes) that were observed in some studies remain a focus of ongoing regulatory review. Long-term effects are not fully established for some indications, and research is ongoing to further characterize long-term safety and outcome patterns.

Frequently Asked Questions (FAQ)

Common questions about Aeron (FAQ)

Q: Does Aeron need to be taken with food, or can it be taken on an empty stomach?

According to the official product information, the 10 mg film-coated tablet can be taken with or without food, as a standard meal does not influence its absorption. The prescribing information for the lower-dose granules (4 mg and 5 mg) describes specific preparation requirements, including mixing with certain soft foods and consuming them promptly.

Q: Are there certain types of foods I should avoid while using Aeron?

Official literature states that there are no known reports of food-food interactions with Montelukast (Aeron). Although taking the medication with a high-fat meal may slightly delay the time it takes for the drug to reach its peak concentration in the body, its overall effectiveness is unchanged.

Q: Can Aeron be split or crushed, according to the official instructions?

Aeron is available in several forms: film-coated tablets, chewable tablets, and granules. The standard film-coated tablets are not described in official instructions as scored, split, or crushed. If an individual cannot swallow a tablet whole, the prescribing information notes the availability of chewable tablets or granules, which are intended for easier administration.

Q: Is Aeron an antibiotic or something else?

Aeron (Montelukast) is not an antibiotic. It is described in official documents as belonging to a class of medicines called leukotriene receptor antagonists (LTRAs). This means it works by inhibiting substances in the body that can cause inflammation and tightening of the airways.

Q: How quickly does Aeron start to work after the first dose?

For the prevention of exercise-induced breathing difficulty (EIB), the prescribing information describes a dosage protocol involving administration at least 2 hours before exercise. For the chronic, or long-term, treatment of asthma, clinical improvement in symptoms is reported to be evident within the first day of starting therapy.

Q: Does Aeron stay in your system for a long time?

The mean time the drug takes to be reduced by half in the bloodstream, known as the half-life, is described as relatively short, typically ranging from 2.7 to 5.5 hours in healthy young adults. The drug is eliminated from the body almost exclusively through bile.

Q: Are the side effects of Aeron generally mild or severe?

Official warnings describe a risk of serious behavior and mood-related changes (neuropsychiatric reactions), which have been reported as severe. However, many patients also experience more common, non-serious effects like upper respiratory infection, headache, or fever. Official warnings about neuropsychiatric changes are publicly available, and these encourage increased vigilance regarding changes in behavior or mood.

Q: What is the most commonly reported side effect of Aeron?

Based on regulatory documents detailing clinical trials, some of the most commonly reported non-specific side effects include upper respiratory infection, headache, sore throat, and fever. The specific frequency of these effects can vary depending on the patient group and condition being treated.

Q: Does Aeron have any warnings about use with alcohol?

The official prescribing information does not list a direct interaction with alcohol. However, reports of liver injury have occurred in patients, and it is noted that many of these individuals had pre-existing risk factors, such as alcohol use. Patients who have questions about alcohol consumption should refer to their healthcare provider for personalized guidance.

Q: What over-the-counter pain relievers interact with Aeron?

Official patient information mentions a warning for individuals with asthma who are known to have a sensitivity to aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). The warning states that sensitive individuals should continue to avoid these substances, as the drug does not protect against this type of reaction.

Q: Can people who have liver problems use Aeron?

Regulatory information indicates that patients with mild-to-moderate liver impairment may have decreased metabolism of the drug, but typically no dosage adjustment is required for these specific patients. The effects in more severe liver impairment have not been fully evaluated in clinical studies.

Q: Is Aeron suitable for use in elderly patients?

Studies indicate that the way the drug is absorbed and processed in the body is similar in elderly patients and younger adults. Due to this similarity in pharmacokinetics, a specific dosage adjustment in the elderly is not generally required.

Q: What are the main contraindications for Aeron?

A contraindication is a condition or factor that prevents the use of a drug. The main contraindication for Aeron is a known hypersensitivity (allergic reaction) to Montelukast or any of the components of the formulation.

Q: Are there long-term health effects associated with using Aeron?

Aeron is intended for long-term management of chronic conditions under professional supervision. Safety monitoring continues, with a key focus on the risk of long-term neuropsychiatric reactions, as this is a specific warning area. The drug is intended for long-term use under professional supervision.

Q: What do the official guidelines say about stopping Aeron treatment?

Official patient information states that patients are not to discontinue the medication or reduce the dose of any other prescribed asthma or allergy medicines, even if symptoms improve. Discontinuation of treatment is determined by a healthcare professional.

Q: Can I take Aeron if I am pregnant or breastfeeding?

Available data from reports regarding use during pregnancy and lactation have not identified a drug-associated risk of major birth defects or other adverse maternal or fetal outcomes. Official guidance notes that patients who are pregnant or breastfeeding are to seek a review from a healthcare provider regarding the risks and benefits.

Q: What happens if I accidentally take two doses of Aeron?

Reports indicate that potential adverse effects following an overdose may include abdominal pain, somnolence (drowsiness), headache, vomiting, thirst, and psychomotor hyperactivity (agitation). Effects have been reported following accidental overdose.

Q: Does taking Aeron affect my ability to drive or operate machinery?

The official patient information includes a warning that if rare side effects occur, such as hallucinations, tremors, dizziness, or an inability to concentrate, driving or operating machinery may be impaired. The drug does not usually affect driving ability.

Q: What are the major black box warnings or special alerts for Aeron?

The drug carries a Boxed Warning (Black Box), which is the FDA's strongest safety warning. This alert is about the risk of serious behavior and mood-related changes (neuropsychiatric events), including suicidal thoughts and actions. The warning describes that vigilance for these types of symptoms is required by the patient and caregiver.

Q: What is the main reason people are prescribed Aeron?

According to official regulatory documents, Aeron is indicated for the prevention and long-term management of asthma. It is also approved for the prevention of exercise-induced bronchoconstriction (EIB), which is breathing difficulty brought on by exercise.

Q: Is there a risk of allergic reactions with Aeron?

Yes, official safety information indicates that one of the main reasons the drug should not be used (a contraindication) is if the patient has a known hypersensitivity or allergic reaction to the active ingredient, Montelukast, or any of the other components in the medicine.

Q: Does Aeron interfere with laboratory blood tests?

The official product literature states that Montelukast is not known to interact with any standard laboratory blood tests. However, standard protocols involve disclosing all medications being taken before any testing.

Q: Is Aeron a treatment or a cure for the condition it addresses?

The drug is officially indicated for the prophylaxis (prevention) and chronic treatment of asthma and EIB. Official drug labels describe its purpose in managing these conditions, but the label does not use the term 'cure'.

How should Aeron be stored and disposed of?

How to Store and Dispose of Aeron?

Because authoritative regulatory documents for a drug specifically named 'Aeron' are unavailable, the official storage and disposal guidelines adhere to the mandatory requirements for all controlled or hazardous pharmaceuticals.

Official Storage and Handling

Secure Storage: Controlled substances must be kept in a physically secure location, protected from unauthorized access, to prevent diversion. This helps prevent access by children and others.
Container Integrity: Keep the item in its original or a clearly labeled, sealed container until disposal.

Mandatory Disposal

Prohibited Disposal: Do not dispose of hazardous pharmaceutical waste by flushing it down a toilet or pouring it down a sink, as this is prohibited by environmental regulations.
Authorized Channels: Disposal must be completed through government-authorized methods or registered entities, such as DEA-registered reverse distributors or via approved destruction processes like incineration, to ensure complete destruction and regulatory compliance.

Aeron